# Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial

## TL;DR

This study explores how Cerebrolysin affects the timing of anticoagulation after stroke, particularly in patients at high risk of bleeding.

## Contribution

The study introduces a novel method to model hemorrhagic transformation risk and identifies Cerebrolysin's potential to allow earlier anticoagulation in high-risk stroke patients.

## Key findings

- Cerebrolysin significantly reduced symptomatic and any hemorrhagic transformation in high-risk patients.
- Cerebrolysin shortened the hazardous period and advanced the risk-equilibrium point by 1–2 days in high-risk patients.
- In low-risk patients, both groups reached stable hazard by day 2.

## Abstract

The optimal timing of anticoagulation resumption after acute ischemic stroke remains uncertain, particularly in patients at elevated risk of hemorrhagic transformation (HT). Although Cerebrolysin reduces HT incidence, its influence on dynamic HT risk and the safe anticoagulation window remains unclear.

This post hoc secondary survival analysis of the CEREHETIS trial (ISRCTN87656744) included 238 patients with intravenous thrombolysis (IVT)–treated middle cerebral artery (MCA) infarction. Patients were categorized into low (HTI 0) and high (HTI 1–4) HT-risk groups. Fourteen-day HT hazard trajectories were modeled using the Gompertz distribution. Nonlinear hazard acceleration (NLHA) and the compounding effect—reflecting self-amplifying instantaneous risk—were used to identify the inception point at which hazard stabilization may permit anticoagulation. A conservative NLHA threshold (0.23%–0.44%/day) defined this risk-equilibrium.

In high-risk patients, Cerebrolysin significantly reduced symptomatic HT (HR 0.245; 95% CI 0.072–0.837; p = 0.020) and any HT (HR 0.543; 95% CI 0.297–0.991; p = 0.032). In controls, the compounding effect peaked on day 1 and persisted into day 2, whereas Cerebrolysin attenuated this amplification and shortened the hazardous period. Inception points occurred on days 1–3 with Cerebrolysin vs. days 3–5 in controls. In low-risk patients, both groups reached stable hazard by day 2.

In IVT-treated MCA stroke patients with HTI 1–4, Cerebrolysin may reduce HT hazard and advance the risk-equilibrium point by approximately 1–2 days. These findings are preliminary and hypothesis-generating, suggesting that Cerebrolysin may allow earlier—but individualized—anticoagulation resumption in selected high-risk patients, pending prospective validation.

Conceptual summary table illustrating analogies, statistical concepts, and clinical interpretations related to hemorrhagic transformation (HT) risk. A steaming mug labeled “Low risk” is shown alongside a hotter cup labeled “High risk”, with an ice cube depicted nearby. The table links everyday analogies (temperature, tea volume, cooling rate) to statistical measures (HT hazard, hazard acceleration, compounding effect) and their clinical implications for HT risk management. Clinical scenarios describe how low- and high-risk states influence cooling and stabilization processes in the context of HT after ischemic stroke.